PURPOSE: Results of efficacy and safety assessments of topical sevoflurane use in patients with long-term treatment-refractory vascular ulcers are reported. METHODS: Patients were randomly assigned to receive sevoflurane instillations (1 mL per cm2 of ulcer area 1-4 times daily) plus standard wound care (ulcer cleaning, debridement, and dressing changes) or standard care only. Topical sevoflurane was initiated during hospitalization, with self- or nurse-administered instillations continued after discharge. Study participants were evaluated at least once weekly for 1 month and then every 2 weeks for up to 90 days. The primary efficacy measures were debridement-related and overall pain (assessed using a 10-point visual analog scale), daily opioid use, and ulcer size; secondary measures were patient and clinician impressions of improvement and ulcer-related admissions during treatment. The primary safety endpoint was intolerable sevoflurane-related adverse effects. RESULTS: Compared with the group receiving standard care alone (n = 5), the sevoflurane group (n = 10) had significant (p = 0.001) reductions in mean ± S.D. scores for debridement-related pain on day 1 of treatment and at subsequent time points; the sevoflurane group also had significant reductions in overall pain, daily opioid use, and ulcer size. Outcomes in terms of patient- and clinician-rated improvement and emergency admissions also favored the sevoflurane group. Mild localized reddening in the area surrounding ulcers occurred in 4 sevoflurane-treated patients. CONCLUSION: Direct application of sevoflurane onto vascular ulcers resulted in an intense and long-lasting analgesia and was associated with a progressive reduction of ulcer size.
RCT Entities:
PURPOSE: Results of efficacy and safety assessments of topical sevoflurane use in patients with long-term treatment-refractory vascular ulcers are reported. METHODS:Patients were randomly assigned to receive sevoflurane instillations (1 mL per cm2 of ulcer area 1-4 times daily) plus standard wound care (ulcer cleaning, debridement, and dressing changes) or standard care only. Topical sevoflurane was initiated during hospitalization, with self- or nurse-administered instillations continued after discharge. Study participants were evaluated at least once weekly for 1 month and then every 2 weeks for up to 90 days. The primary efficacy measures were debridement-related and overall pain (assessed using a 10-point visual analog scale), daily opioid use, and ulcer size; secondary measures were patient and clinician impressions of improvement and ulcer-related admissions during treatment. The primary safety endpoint was intolerable sevoflurane-related adverse effects. RESULTS: Compared with the group receiving standard care alone (n = 5), the sevoflurane group (n = 10) had significant (p = 0.001) reductions in mean ± S.D. scores for debridement-related pain on day 1 of treatment and at subsequent time points; the sevoflurane group also had significant reductions in overall pain, daily opioid use, and ulcer size. Outcomes in terms of patient- and clinician-rated improvement and emergency admissions also favored the sevoflurane group. Mild localized reddening in the area surrounding ulcers occurred in 4 sevoflurane-treated patients. CONCLUSION: Direct application of sevoflurane onto vascular ulcers resulted in an intense and long-lasting analgesia and was associated with a progressive reduction of ulcer size.
Authors: F Dámaso Fernández-Ginés; Manuel Cortiñas-Sáenz; Desirée Agudo-Ponce; Ana Navajas-Gómez de Aranda; José A Morales-Molina; Carmen Fernández-Sánchez; Francisco Sierra-García; Héctor Mateo-Carrasco Journal: Int Wound J Date: 2019-11-25 Impact factor: 3.315
Authors: F Dámaso Fernández-Ginés; Manuel Cortiñas-Sáenz; Ana Navajas-Gómez de Aranda; Maria Del Carmen Navas-Martinez; José Antonio Morales-Molina; Francisco Sierra-García; Héctor Mateo-Carrasco Journal: Eur J Hosp Pharm Date: 2018-01-11
Authors: Lucía Quintana-Castanedo; Lorena Recarte-Marín; Laura Pérez-Jerónimo; Elena Conde-Montero; Pablo de la Cueva-Dobao Journal: Int Wound J Date: 2019-08-14 Impact factor: 3.315
Authors: Mayank Aranke; Cynthia T Pham; Melis Yilmaz; Jason K Wang; Vwaire Orhurhu; Daniel An; Elyse M Cornett; Alan David Kaye; Anh L Ngo; Farnad Imani; Reza Farahmand Rad; Giustino Varrassi; Omar Viswanath; Ivan Urits Journal: Anesth Pain Med Date: 2021-02-24
Authors: Gill Norman; Maggie J Westby; Amber D Rithalia; Nikki Stubbs; Marta O Soares; Jo C Dumville Journal: Cochrane Database Syst Rev Date: 2018-06-15
Authors: Dámaso Fernández-Ginés; Carmen Selva-Sevilla; Manuel Cortiñas-Sáenz; Manuel Gerónimo-Pardo Journal: Med Lav Date: 2019-10-29 Impact factor: 1.275